



Editor

Tore K Kvien

Associate Editors

Francis Berenbaum
Hans Bijlsma
David Pisetsky
Dimitrios Boumpas
Gerd Burmester
Mary Crow
Iain McInnes

Editorial office

Annals of the Rheumatic Diseases
BMJ Publishing Group Ltd
BMA House
Tavistock Square
London WC1H 9JR, UK
T: +44 (0)20 7383 6250
F: +44 (0)20 7383 6668
E: ard@bmj.com
Twitter: @ARD_BMJ
ISSN: 0003-4967 (print)
ISSN: 1468-2060 (online)
Impact Factor: 10.377

Disclaimer: ARD is owned and published by BMJ Publishing Group Ltd (a wholly owned subsidiary of the British Medical Association) and the European League Against Rheumatism. The owners grant editorial freedom to the Editor of ARD. ARD follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

ARD is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions the BMJ Publishing Group, the European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury or damage resulting from the use of ARD or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Copyright: © 2016 BMJ Publishing Group and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying recording, or otherwise without prior permission

ARD is published by BMJ Publishing Group Ltd typeset by Techset and printed in the UK on acid-free paper.

Annals of the Rheumatic Diseases (ISSN No: 0003-4967) is published monthly by BMJ Publishing Group and distributed in the USA by Air Business Ltd. Periodicals postage paid at Jamaica NY 11431
POSTMASTER: send address changes to *Annals of the Rheumatic Diseases*, Air Business Ltd, c/o Worldnet Shipping Inc., 156-15, 146th Avenue, 2nd Floor, Jamaica, NY 11434, USA.



Receive regular table of contents by email.
Register using this QR code.

Editorial

- 2103** Remission in SLE: closing in on the target
R F van Vollenhoven, A Voskuyl, E Morand, C Aranow

Review

- 2107** Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
K L Winthrop, S A Novosad, J W Baddley, L Calabrese, T Chiller, P Polgreen, F Bartalesi, M Lipman, X Mariette, O Lortholary, M E Weinblatt, M Saag, J Smolen

Clinical and epidemiological research

- 2117** Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
M Zen, L Iaccarino, M Gatto, S Bettio, L Nalotto, A Ghirardello, L Punzi, A Doria
- 2123** OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy
P C Taylor, M C Genovese, M Greenwood, M Ho, E Nasonov, B Oemar, R Stoilov, J Vencovsky, M Weinblatt
- 2130** Association between tobacco smoking and response to tumour necrosis factor α inhibitor treatment in psoriatic arthritis: results from the DANBIO registry
P Højgaard, B Glimborg, M L Hetland, T H Hansen, P R Lage-Hansen, M H Petersen, M Holland-Fischer, C Nilsson, A G Lof, B N Andersen, T Adalsten, J Jensen, E Omerovic, R Christensen, U Tarp, R Østgård, L Dreyer
- 2137** TNF inhibitor therapy and risk of breast cancer recurrence in patients with rheumatoid arthritis: a nationwide cohort study
P Raaschou, T Frisell, J Askling, for the ARTIS Study Group
- 2144** Development of a patient-reported outcome measure of tophus burden: the Tophus Impact Questionnaire (TIQ-20)
O Aati, W J Taylor, R J Siegel, A Horne, M E House, P Tan, J Drake, L K Stamp, N Dalbeth
- 2151** Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA
C Hecht, M Englbrecht, J Rech, S Schmidt, E Araujo, K Engelke, S Finzel, G Schett
- 2157** Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin
W-H Chung, W-C Chang, S L Stocker, C-G Juo, G G Graham, M-H H Lee, K M Williams, Y-C Tian, K-C Juan, Y-J Wu, C-H Yang, C-J Chang, Y-J Lin, R O Day, S-I Hung

- 2165** Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?
P Emery, A Kavanaugh, Y Bao, A Ganguli, P Mulani

- 2175** Safety, tolerability and potential efficacy of injection of autologous adipose-derived stromal vascular fraction in the fingers of patients with systemic sclerosis: an open-label phase I trial
B Granel, A Daumas, E Jouve, J-R Harlé, P-S Nguyen, C Chabannon, N Colavolpe, J-C Reynier, R Truillet, S Mallet, A Baiada, D Casanova, L Giraud, L Arnaud, J Veran, F Sabatier, G Magalon

- 2183** Estimation of heritability of different outcomes for genetic studies of TNFi response in patients with rheumatoid arthritis
M U Mirkov, L Janss, S H Vermeulen, M A F J van de Laar, P L C M van Riel, H-J Guchelaar, H G Brunner, C A Albers, M J H Coenen

- 2188** Whole-body MRI of patients with polymyalgia rheumatica identifies a distinct subset with complete patient-reported response to glucocorticoids
S L Mackie, C T Pease, E Fukuba, E Harris, P Emery, R Hodgson, J Freeston, D McGonagle

Basic and translational research

- 2193** CD226 (DNAM-1) is associated with susceptibility to juvenile idiopathic arthritis
T H C M Reinards, H M Albers, D M C Brinkman, S S M Kamphuis, M A J van Rossum, H J Girschick, C Wouters, E P A H Hoppenreijns, R K Saurenmann, A Hinks, J A Ellis, E Bakker, W Verduijn, P Slagboom, T W J Huizinga, R E M Toes, J J Houwing-Duistermaat, R ten Cate, M W Schilham
- 2199** Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice
J S Knight, V Subramanian, A A O'Dell, S Yalavarthi, W Zhao, C K Smith, J B Hodgkin, P R Thompson, M J Kaplan
- 2207** A homeostatic function of CXCR2 signalling in articular cartilage
J Sherwood, J Bertrand, G Nalesso, B Poulet, A Pitsillides, L Brandolini, A Karystinou, C De Bari, F P Luyten, C Pitzalis, T Pap, F Dell'Accio

MORE CONTENTS ►

This article has been chosen by the Editor to be of special interest or importance and is freely available online.

This article has been made freely available online under the BMJ Journals Open Access scheme. See <http://ard.bmj.com/site/about/guidelines.xhtml#open>

C O P E COMMITTEE ON PUBLICATION ETHICS

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>

equator network

recycle
When you have finished with this please recycle it

The online version of this article contains multiple choice questions hosted on BMJ Learning.

- 2216** FHL2 regulates the resolution of tissue damage in chronic inflammatory arthritis
V Wixler, C Cromme, E Retser, L-H Meyer, N Smyth, K Mühlberg, A Korb-Pap, C Koers-Wunrau, Y Sotsios, R Bassel-Dubby, D Baeten, P P Tak, B Niederreiter, K Redlich, J Bertrand, B V Skryabin, S Ludwig, T Pap
- 2224** NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF- β receptor signalling
M Lech, G Lorenz, O P Kulkarni, M O O Grosser, N Stigrot, M N Darisipudi, R Günthner, M W M Wintergerst, D Anz, H E Susanti, H-J Anders
- 2236** B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related disease
E Della-Torre, E Feeney, V Deshpande, H Mattoo, V Mahajan, M Kulikova, Z S Wallace, M Carruthers, R T Chung, S Pillai, J H Stone
- 2244** Progranulin protects against osteoarthritis through interacting with TNF- α and β -Catenin signalling
Yun-peng Zhao, B Liu, Qing-yun Tian, Jian-lu Wei, B Richbrough, Chuan-ju Liu
- 2254** Prophylactic treatment with S100A9 inhibitor paquinimod reduces pathology in experimental collagenase-induced osteoarthritis
R F Schelbergen, E J Geven, M H J van den Bosch, H Eriksson, T Leanderson, T Vogl, J Roth, F A J van de Loo, M I Koenders, P M van der Kraan, W B van den Berg, A B Blom, P L E M van Lent

Letters

- 2260** Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis
N van Herwaarden, C A M Bouman, A van der Maas, R F van Vollenhoven, J W Bijlsma, F H J van den Hoogen, A A den Broeder, B J F van den Bent
- 2261** Immunogenicity, drug trough levels and therapeutic response in patients with rheumatoid arthritis or ankylosing spondylitis after 24-week golimumab treatment
D-Y Chen, Y-M Chen, W-T Hung, H-H Chen, C-W Hsieh, Y-H Chen, W-N Huang, T-Y Hsieh

Electronic pages

Correspondence

- e64** The effect of synovial tissue volume shrinking on pain relief for knee osteoarthritis was overestimated or not?
J Wei, C Zeng, Guang-hua Lei
- e65** Response to: 'The effect of synovial tissue volume shrinking on pain relief for knee osteoarthritis was overestimated or not?' by Wei *et al*
T W O'Neill, M J Parkes, N Maricar, E J Marjanovic, R Hodgson, A D Gait, T F Coates, C E Hutchinson, D T Felson
- e66** The definition of remission in psoriatic arthritis: can this be accurate without assessment of multiple domains?
P S Helliwell, L C Coates
- e67** Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates
M M Schoels, D Aletaha, J S Smolen
- e68** Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?
L van Hoeven, B W Koes, J MW Hazes, A EAM Weel
- e69** Defining an optimal referral strategy for patients with a suspicion of axial spondyloarthritis: what is really important? Response to: 'Evaluating the ASAS recommendations for early referral of axial spondyloarthritis in patients with chronic low back pain; is one parameter present sufficient for primary care practice?' by van Hoeven *et al*
D Poddubnyy, A van Tubergen, R Landewé, J Sieper, D van der Heijde
- e70** Role of nerve growth factor and tropomyosin receptor kinase A in the pathogenesis of osteoarthritis. Might nerve growth factor be the link intertwining obesity and osteoarthritis?
F Iannone, S Perniola, G Lopalco, L Cantarini, G Lapadula
- e71** Response to: 'Role of nerve growth factor (NGF) and tropomyosin receptor kinase A (TrkA) in the pathogenesis of osteoarthritis. Might NGF be the link intertwining obesity and OA?' by Iannone *et al*
L N Nwosu, D A Walsh